Skip to main content
Erschienen in: Rheumatology International 5/2015

01.05.2015 | Original Article - Cases with a Message

Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up

verfasst von: Veronica Silva Vilela, Sergio Prieto-González, José C. Milisenda, Albert Selva-O´Callaghan, Josep M. Grau

Erschienen in: Rheumatology International | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to explore whether polymyositis may be considered as an isolated, organ-specific disease or more suitably as a secondary or associated entity. A retrospective re-evaluation of all the muscle biopsies performed at the Hospital Clínic of Barcelona showing histopathological pattern of polymyositis from January 1997 to May 2012 was carried out. The medical records of the patients with the aforementioned pathological pattern were also reviewed. From 1.290 muscle biopsies performed during the period evaluated, 36 with polymyositis pattern were identified. At the time of muscle biopsy, polymyositis pattern was secondary or associated with other disease in 26 patients and was classified as isolated in the remaining ten patients. After pathological re-evaluation and long-term clinical follow-up, only one patient remained with this diagnosis. Overall, the main final diagnosis related to the initial polymyositis pattern was inflammatory myopathy associated with connective tissue disease. Several other associated conditions were also identified. Isolated polymyositis is highly uncommon. Ruling out potential associated or confusing entities, like inclusion body myositis, overlap syndromes, infections, and cancer, is mandatory.
Literatur
1.
Zurück zum Zitat Milisenda JC, Selva-´Callaghan A, Grau JM (2014) The diagnosis and classification of polymyositis. J Autoimmun 48–49:118–121CrossRefPubMed Milisenda JC, Selva-´Callaghan A, Grau JM (2014) The diagnosis and classification of polymyositis. J Autoimmun 48–49:118–121CrossRefPubMed
2.
Zurück zum Zitat Amato AA, Griggs RC (2003) Unicorns, drag dragons, polymyositis and other mythological beasts. Neurology 61:288–290CrossRefPubMed Amato AA, Griggs RC (2003) Unicorns, drag dragons, polymyositis and other mythological beasts. Neurology 61:288–290CrossRefPubMed
3.
Zurück zum Zitat Van Der Meulen MFG, Bronner IM, Hoogendijk JE et al (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316–321CrossRefPubMed Van Der Meulen MFG, Bronner IM, Hoogendijk JE et al (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316–321CrossRefPubMed
4.
Zurück zum Zitat Kissel JT (2008) Polymyositis: not a unicorn or mythological beast…but maybe a duck ? Neurology 70:414–415CrossRefPubMed Kissel JT (2008) Polymyositis: not a unicorn or mythological beast…but maybe a duck ? Neurology 70:414–415CrossRefPubMed
5.
Zurück zum Zitat Chahin N, Engel (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424CrossRefPubMed Chahin N, Engel (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424CrossRefPubMed
6.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis : first of two parts. N Engl J Med 292:344–347CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis : first of two parts. N Engl J Med 292:344–347CrossRefPubMed
7.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis : second of two parts. N Engl J Med 292:403–407CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis : second of two parts. N Engl J Med 292:403–407CrossRefPubMed
8.
Zurück zum Zitat Heckmann JM, Pillay K, Hearn AP, Kenyon C (2010) Polymyositis in HIV-infected subjects. Neuromuscul Disord 20:735–739CrossRefPubMed Heckmann JM, Pillay K, Hearn AP, Kenyon C (2010) Polymyositis in HIV-infected subjects. Neuromuscul Disord 20:735–739CrossRefPubMed
9.
Zurück zum Zitat Aydintug A, Cervera R, D´Cruz D, Rammírez G et al (1991) Polymyositis complicating D-penicillamine treatment. Postgrad Med 67:1018–1020CrossRef Aydintug A, Cervera R, D´Cruz D, Rammírez G et al (1991) Polymyositis complicating D-penicillamine treatment. Postgrad Med 67:1018–1020CrossRef
10.
Zurück zum Zitat Ishikawa Y, Yukawa N, Ohmura K et al (2009) Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis:a case report and review of literature. Clin Rheumatol 29:563–566CrossRef Ishikawa Y, Yukawa N, Ohmura K et al (2009) Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis:a case report and review of literature. Clin Rheumatol 29:563–566CrossRef
11.
Zurück zum Zitat Vint J, Samson M, Galtier JN et al (2010) Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 29:103–106CrossRef Vint J, Samson M, Galtier JN et al (2010) Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 29:103–106CrossRef
12.
Zurück zum Zitat Chapin JE, Kornfeld M, Harris A (2005) Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 31:266–272CrossRefPubMed Chapin JE, Kornfeld M, Harris A (2005) Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 31:266–272CrossRefPubMed
13.
Zurück zum Zitat Tang YC, Wang SK, Yuan WL, Tang YC, Wang SK (2011) Primary aldosteronism simulating polymyositis. J Rheumatol 38:1529–1533CrossRefPubMed Tang YC, Wang SK, Yuan WL, Tang YC, Wang SK (2011) Primary aldosteronism simulating polymyositis. J Rheumatol 38:1529–1533CrossRefPubMed
14.
Zurück zum Zitat Yunis EJ, Samaha FJ (1971) Inclusion body myositis. Lab Invest 25:240–248PubMed Yunis EJ, Samaha FJ (1971) Inclusion body myositis. Lab Invest 25:240–248PubMed
15.
Zurück zum Zitat Milisenda JC, Prieto-Gonzáles S, Grau JM (2012) Sporadic inclusion body myositis. Semin Fund Esp Reumatol 13:23–30CrossRef Milisenda JC, Prieto-Gonzáles S, Grau JM (2012) Sporadic inclusion body myositis. Semin Fund Esp Reumatol 13:23–30CrossRef
16.
Zurück zum Zitat Miller T, Al-Tozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psichiatr 73:420–428CrossRef Miller T, Al-Tozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psichiatr 73:420–428CrossRef
17.
Zurück zum Zitat Vargas-Leguás H, Selva-O´Callaghan A, Campins-Martí M et al (2007) Polymyositis-dermatomyositis: incidence in Spain (1997–2004). Med Clin (Barc) 129:721–724CrossRef Vargas-Leguás H, Selva-O´Callaghan A, Campins-Martí M et al (2007) Polymyositis-dermatomyositis: incidence in Spain (1997–2004). Med Clin (Barc) 129:721–724CrossRef
18.
Zurück zum Zitat Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:A330–A334CrossRefPubMed Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:A330–A334CrossRefPubMed
19.
Zurück zum Zitat TroyanovY Tragoff I, Tremblay JL, Goulet JR, Raymond Y, Senécal JL (2005) Novel classification of idiopathic inflammatory myositis based on overlap syndrome features and autoantibodies. Analysis of 100 French–Canadian patients. Medicine (Baltimore) 84:231–249CrossRef TroyanovY Tragoff I, Tremblay JL, Goulet JR, Raymond Y, Senécal JL (2005) Novel classification of idiopathic inflammatory myositis based on overlap syndrome features and autoantibodies. Analysis of 100 French–Canadian patients. Medicine (Baltimore) 84:231–249CrossRef
20.
Zurück zum Zitat D´Arcy CE, Ryan MM, McLean CA (2009) Juvenile polymyositis or paediatric muscle dystrophy: a detailed re-analysis of 13 cases. Hystopathology 55:452–462CrossRef D´Arcy CE, Ryan MM, McLean CA (2009) Juvenile polymyositis or paediatric muscle dystrophy: a detailed re-analysis of 13 cases. Hystopathology 55:452–462CrossRef
21.
Zurück zum Zitat Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Beyamine A, Franques J et al (2013) Correlation of clinicoserologic and pathologic classifications on inflammatory myopathies. Medicine (Baltimore) 92:15–24CrossRef Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Beyamine A, Franques J et al (2013) Correlation of clinicoserologic and pathologic classifications on inflammatory myopathies. Medicine (Baltimore) 92:15–24CrossRef
22.
Zurück zum Zitat Carpenter S, Karpati G (2001) Pathology of skeletal muscle, 2nd edn., Oxford University Press, Oxford, ISBN: 0-19506364-3 Carpenter S, Karpati G (2001) Pathology of skeletal muscle, 2nd edn., Oxford University Press, Oxford, ISBN: 0-19506364-3
23.
24.
Zurück zum Zitat Griggs RC, Askanas V, Di Mauro S, Engel A, Karpati G, Mendell G et al (1995) Inclusion body myositis. Ann Neurol 38:705–713CrossRefPubMed Griggs RC, Askanas V, Di Mauro S, Engel A, Karpati G, Mendell G et al (1995) Inclusion body myositis. Ann Neurol 38:705–713CrossRefPubMed
25.
Zurück zum Zitat Averbuch Heller L, Steiner I, Abramsky O (1992) Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 49:1292–1295 Averbuch Heller L, Steiner I, Abramsky O (1992) Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 49:1292–1295
26.
Zurück zum Zitat Clements PJ, Furst DE, Campion DS et al (1978) Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arhtritis Rheum 21:62–71CrossRef Clements PJ, Furst DE, Campion DS et al (1978) Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arhtritis Rheum 21:62–71CrossRef
27.
Zurück zum Zitat Ranque B, Authier F-J, Le-Guern V et al (2009) A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 68:1474–1477CrossRefPubMed Ranque B, Authier F-J, Le-Guern V et al (2009) A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 68:1474–1477CrossRefPubMed
28.
Zurück zum Zitat Meyer A, Meyer N, Schaeffer M, Gottemberg JE, Geny B, Sibilia J (2014) Incidence and prevalence of idiopathic myopathies: a systematic review. Rheumatology 26:261–275 Meyer A, Meyer N, Schaeffer M, Gottemberg JE, Geny B, Sibilia J (2014) Incidence and prevalence of idiopathic myopathies: a systematic review. Rheumatology 26:261–275
29.
Zurück zum Zitat Tan JA, Roberts-Thompson PJ, Blumbergs P, Hakendorf P, Cox SR, Limaye V (2013) Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30 years epidemiologic study of biopsy proven cases. Int J Rheum Dis 16:331–338CrossRefPubMed Tan JA, Roberts-Thompson PJ, Blumbergs P, Hakendorf P, Cox SR, Limaye V (2013) Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30 years epidemiologic study of biopsy proven cases. Int J Rheum Dis 16:331–338CrossRefPubMed
30.
Zurück zum Zitat Linklater H, Pipetone N, Rose MR et al (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumtol 31:767–769 Linklater H, Pipetone N, Rose MR et al (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumtol 31:767–769
Metadaten
Titel
Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up
verfasst von
Veronica Silva Vilela
Sergio Prieto-González
José C. Milisenda
Albert Selva-O´Callaghan
Josep M. Grau
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 5/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3198-5

Weitere Artikel der Ausgabe 5/2015

Rheumatology International 5/2015 Zur Ausgabe

Letter to the Editor - Food for Thought

Intranasal oxytocin and NSAIDs

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.